Janagliflozin (DB16209): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Janagliflozin (DrugBank ID: DB16209) is a novel, orally administered, selective small-molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Developed by Sihuan Pharmaceutical's subsidiary, Huisheng Biopharmaceutical, it is designated as a national Class 1 innovative drug in China.[1] In January 2024, Janagliflozin, under the trade name Huiyoujing®, received drug registration approval from the National Medical Products Administration (NMPA) of China for the treatment of Type 2 Diabetes Mellitus (T2DM). This approval covers its use as both monotherapy and in combination with metformin.[1] The drug remains investigational in other global regions.[2]

Consistent with its therapeutic class, Janagliflozin exerts its antihyperglycemic effect through an insulin-independent mechanism. It selectively inhibits SGLT2 in the proximal renal tubules, which reduces the reabsorption of glucose from the glomerular filtrate, thereby promoting urinary glucose excretion (glucosuria) and lowering plasma glucose concentrations.[5] This mechanism confers a low intrinsic risk of hypoglycemia.

Pivotal Phase 3 clinical trials conducted in Chinese patients with T2DM have demonstrated robust efficacy. As a monotherapy in drug-naive patients, Janagliflozin at 25 mg and 50 mg daily doses achieved statistically significant, placebo-adjusted glycated hemoglobin (HbA1c​) reductions of -0.80% and -0.88%, respectively.[7] When used as an add-on therapy to metformin in patients with inadequate glycemic control, both the 25 mg and 50 mg doses provided an identical placebo-adjusted

HbA1c​ reduction of -0.58%.[8] This glycemic efficacy is accompanied by clinically significant pleiotropic benefits, including reductions in body weight and systolic blood pressure, which are characteristic of the SGLT2 inhibitor class.[7]

The drug exhibits a favorable pharmacokinetic profile that supports a once-daily dosing regimen. It is characterized by rapid absorption, with a median time to maximum concentration (Tmax​) of 2-6 hours, and a long terminal half-life (t1/2​) of approximately 21-30 hours at steady state.[10] A key feature of its profile is that drug exposure is only minimally affected by renal impairment, suggesting pharmacokinetic stability in this important patient subgroup.[10]

In its clinical program, Janagliflozin was generally well-tolerated. No instances of severe hypoglycemia or diabetic ketoacidosis were reported, and the incidence of class-characteristic adverse events, such as urinary tract and genital mycotic infections, was reported to be low.[7]

Strategically, Janagliflozin's development was notably accelerated through the application of a Model-Informed Drug Development (MIDD) strategy, which successfully supported a waiver for a dedicated Phase 2 study.[14] Its approval marks it as the second domestically developed SGLT2 inhibitor in China, positioning Sihuan Pharmaceutical to compete in a rapidly expanding therapeutic market.[1]

Introduction to Janagliflozin and the SGLT2 Inhibitor Class

The Global Burden of Type 2 Diabetes and Therapeutic Gaps

Type 2 Diabetes Mellitus (T2DM) represents a significant and escalating global health crisis, with a particularly high prevalence and growing incidence in China. The management of T2DM has historically relied on therapeutic agents that primarily modulate insulin secretion or sensitivity. While effective, many older antidiabetic agents are associated with limitations such as the risk of hypoglycemia (e.g., sulfonylureas, insulin), weight gain (e.g., sulfonylureas, thiazolidinediones, insulin), and a progressive loss of efficacy over time due to the natural history of beta-cell decline. These limitations have driven the search for novel therapeutic approaches that can provide durable glycemic control with an improved safety profile and offer benefits beyond simple glucose lowering, particularly in the realms of cardiovascular and renal protection.

Development by Sihuan Pharmaceutical

Janagliflozin emerged from this therapeutic landscape as a product of Sihuan Pharmaceutical Holdings Group, a major Chinese pharmaceutical manufacturer, through its non-wholly owned subsidiary, Huisheng Biopharmaceutical.[2] Positioned as a "national Class 1 innovative drug," Janagliflozin's development and approval signify a strategic pivot within China's pharmaceutical industry from a focus on generic manufacturing towards domestic innovation to address critical public health challenges.[1] As the second self-developed SGLT2 inhibitor to be approved and marketed in China, it represents a significant milestone for Huisheng Biopharmaceutical and a competitive entry into the rapidly growing domestic market for this drug class, which saw a 46% increase in sales in sample hospitals in 2022.[1] This development reflects a deliberate industrial strategy to meet the demands of a large patient population with a domestically originated therapeutic, thereby reducing reliance on foreign-developed pharmaceuticals and capturing a lucrative market.

The SGLT2 Inhibition Paradigm

Physiology of Renal Glucose Handling

Under normal physiological conditions, the kidneys play a crucial role in glucose homeostasis. Approximately 180 grams of glucose are filtered daily by the glomeruli and subsequently reabsorbed back into circulation via specialized transporters in the proximal convoluted tubules. This reabsorption process is mediated primarily by two sodium-glucose cotransporters: SGLT1 and SGLT2. SGLT2, a high-capacity, low-affinity transporter located in the early (S1) segment of the proximal tubule, is responsible for reabsorbing approximately 90% of the filtered glucose.[6] The remaining 10% is reabsorbed by SGLT1, a low-capacity, high-affinity transporter located further down the tubule. In patients with T2DM, the expression and activity of SGLT2 are pathologically upregulated, which exacerbates hyperglycemia by increasing the capacity for renal glucose reabsorption.[17]

Therapeutic Rationale

The SGLT2 inhibitor class of drugs, including Janagliflozin, was developed to specifically target this renal mechanism. By competitively and selectively inhibiting the SGLT2 protein, these agents reduce the reabsorption of glucose from the glomerular filtrate.[5] This action effectively lowers the renal threshold for glucose (RTG), the plasma glucose concentration above which glucose begins to appear in the urine. The result is a significant increase in urinary glucose excretion (glucosuria), leading to a net loss of glucose and calories from the body.[17] A key feature of this mechanism is that it is independent of insulin secretion and beta-cell function, which confers two major advantages: a very low intrinsic risk of hypoglycemia when used as monotherapy, and continued efficacy across different stages of T2DM, even in patients with diminished beta-cell reserve.[20]

Class-Wide Pleiotropic Effects

The therapeutic benefits of SGLT2 inhibition extend far beyond glycemic control. The induced glucosuria creates an osmotic diuresis, leading to a modest reduction in intravascular volume and blood pressure.[5] The associated caloric loss contributes to weight reduction. These hemodynamic and metabolic effects are believed to underpin the profound and now well-established cardiovascular and renal protective benefits of the class. Landmark clinical trials for other SGLT2 inhibitors have demonstrated significant reductions in major adverse cardiovascular events (MACE), hospitalizations for heart failure (HHF), and the progression of chronic kidney disease (CKD).[10] These findings have fundamentally transformed the role of SGLT2 inhibitors, elevating them from purely antihyperglycemic agents to foundational therapies in the management of heart failure and CKD, irrespective of a patient's diabetic status.

Chemical and Physical Characterization

A comprehensive understanding of Janagliflozin begins with its precise chemical identity and physicochemical properties, which dictate its pharmacological behavior and suitability as an oral therapeutic agent.

Structural and Molecular Identity

Janagliflozin is classified as a small molecule drug.[25] Its structure is a C-glucoside derivative, a common feature of the gliflozin class, which provides stability against enzymatic degradation compared to O-glucosides. The molecule's precise stereochemistry and atomic connectivity are defined by its International Union of Pure and Applied Chemistry (IUPAC) name: (2S,3R,4R,5S,6R)-2-hexanyl]oxy]phenyl]methyl]-4-chlorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol.[2] This complex structure consists of a central glucose moiety linked via a carbon-carbon bond to a substituted aromatic system, which includes a bicyclo[3.1.0]hexane group. Its molecular formula is

C25​H29​ClO6​, corresponding to a molar mass of 460.95 g·mol⁻¹.[2]

Physicochemical Properties and Druglikeness

The physicochemical profile of Janagliflozin is consistent with that of a modern, orally bioavailable drug. Analysis of its structure reveals properties conducive to absorption and distribution. It has 6 hydrogen bond acceptors and 4 hydrogen bond donors, with a topological polar surface area (TPSA) of 99.38 A˚2.[25] The calculated partition coefficient (XLogP of 1.82) indicates a balance between hydrophilicity and lipophilicity necessary for membrane permeation and solubility.[27] These parameters contribute to its favorable "druglikeness" profile. The molecule adheres to Lipinski's Rule of Five, with zero violations reported, as well as the Ghose Filter and MDDR-like Rule, further supporting its suitability as an oral medication.[25]

Synthesis Pathway

The chemical synthesis of Janagliflozin has been described as a multi-step process designed for efficiency and scalability, which are critical for commercial manufacturing. The route involves the coupling of two advanced intermediates under cryogenic conditions using n-butyllithium (nBuLi).[3] Key transformations in the synthesis include a Friedel–Crafts acylation to form a ketone intermediate, followed by a reduction step using triethylsilane and boron trifluoride–diethyl etherate.[3] The final step is a hydrolysis of an acetylated precursor using lithium hydroxide monohydrate in a mixed solvent system, which proceeds with a high yield of 91%. The overall synthetic route is notably described as "protection-group-free," which simplifies the process, reduces the number of steps, and improves overall efficiency, making it well-suited for large-scale production.[3]

Property	Value	Source(s)
DrugBank ID	DB16209	2
Type	Small Molecule	25
IUPAC Name	(2S,3R,4R,5S,6R)-2-hexanyl]oxy]phenyl]methyl]-4-chlorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol	2
CAS Number	1800115-22-3	2
Chemical Formula	C25​H29​ClO6​	2
Molar Mass	460.95 g·mol⁻¹	2
InChIKey	WDBIPGHUEJEKTC-VWQPKTIXSA-N	2
Canonical SMILES	C1=C(C=CC(=C1)OC2C[C@H]3C[C@H]3C2)CC4=CC(=CC=C4Cl)[C@H]5C@@HO
Hydrogen Bond Acceptors	6
Hydrogen Bond Donors	4
Rotatable Bonds	6
Topological Polar Surface Area	99.38 A˚2
XLogP	1.82
Lipinski's Rule of Five	Yes (0 violations)

Non-Clinical and Clinical Pharmacology

The pharmacological profile of Janagliflozin defines its therapeutic effects and clinical utility. This profile is characterized by its specific mechanism of action, its quantifiable effects on physiological biomarkers (pharmacodynamics), and its absorption, distribution, metabolism, and excretion (pharmacokinetics) within the human body.

Mechanism of Action

Janagliflozin's primary molecular target is the sodium-glucose cotransporter 2 (SGLT2), encoded by the SLC5A2 gene. As a highly selective inhibitor of this transporter, Janagliflozin functions by competitively binding to SGLT2 proteins located on the apical membrane of epithelial cells in the S1 segment of the proximal renal tubule. The drug's chemical structure includes a glucose-mimicking moiety, which facilitates this binding and blocks the transporter's normal function of reabsorbing glucose from the glomerular filtrate back into the bloodstream.

By inhibiting SGLT2, Janagliflozin effectively prevents the reabsorption of approximately 90% of the glucose that is filtered by the kidneys. This leads to a substantial increase in urinary glucose excretion (glucosuria) and a lowering of the renal threshold for glucose (RTG), the plasma glucose level at which glucosuria begins. The resulting therapeutic effects include a reduction in plasma glucose levels, a modest osmotic diuretic effect due to the increased solute load in the urine, and a net caloric loss, which contributes to observed reductions in body weight and systolic blood pressure. This entire mechanism is independent of pancreatic beta-cell function and insulin levels, which is a hallmark of the SGLT2 inhibitor class.

Pharmacodynamics

The pharmacodynamic (PD) effects of Janagliflozin have been well-characterized in clinical studies, demonstrating a clear and quantifiable impact on glucose handling.

Urinary Glucose Excretion (UGE): The primary PD effect of Janagliflozin is a dose-dependent increase in 24-hour UGE. In single-ascending dose studies in healthy Chinese subjects, the mean 24-hour UGE ranged from approximately 18 g to 85 g across doses from 10 mg to 450 mg. A critical finding is the saturation of this effect at higher doses. At steady state, mean 24-hour UGE in healthy subjects was approximately 40 g, 43 g, and 50 g for the 25 mg, 50 mg, and 100 mg doses, respectively, indicating a plateauing of the effect above the 25 mg dose. This observation was mirrored in T2DM patients, where multiple doses of 25 mg and 50 mg Janagliflozin produced nearly identical increases in 24-hour UGE from baseline (92.35 g and 94.17 g, respectively). These effects were comparable to those of dapagliflozin 10 mg (87.61 g). This PD plateau provides a strong mechanistic basis for the clinical finding that the 50 mg dose offers little to no additional glycemic benefit over the 25 mg dose in certain settings.

Glycemic and Metabolic Parameters: As a direct consequence of increased UGE, Janagliflozin treatment leads to significant reductions in both fasting plasma glucose (FPG) and 2-hour postprandial glucose (PPG).

Renal Function: Consistent with the SGLT2 inhibitor class, Janagliflozin can cause a transient, short-term reduction in the glomerular filtration rate (GFR) upon initiation. This effect is considered hemodynamic in nature, related to tubuloglomerular feedback, and typically stabilizes over time or reverses upon discontinuation of the drug. Importantly, Janagliflozin has been shown to maintain a significant pharmacologic effect, as measured by UGE, even in patients with moderate renal impairment (e.g., eGFR between 30 and 44 mL/min/1.73 m²), indicating that the drug remains active at the renal tubule despite reduced overall filtration.

Pharmacokinetics

The pharmacokinetic (PK) profile of Janagliflozin is well-suited for a once-daily oral antidiabetic agent.

Absorption, Distribution, Metabolism, and Excretion (ADME):

• Absorption: Janagliflozin is rapidly absorbed following oral administration, with the time to reach maximum plasma concentration (Tmax​) occurring at a median of 2.0 to 6.0 hours in both healthy subjects and patients with T2DM.
• Metabolism: A metabolite, designated XZP-5185, has been identified in plasma. While specific pathways for Janagliflozin are not detailed, by analogy with other gliflozins such as canagliflozin, metabolism is likely dominated by O-glucuronidation via UGT enzymes, with minimal involvement of the cytochrome P450 system.
• Elimination: The drug exhibits a long mean terminal half-life (t1/2​) at steady state, estimated to be between 21 and 30 hours. This long half-life provides consistent drug exposure over a 24-hour period and strongly supports a once-daily dosing regimen.
• Dose Proportionality and Accumulation: Plasma exposure, as measured by the area under the curve (AUC), increases in a manner that is roughly proportional to the dose. With once-daily dosing, there is no significant accumulation, with reported accumulation factors of less than 2.

Pharmacokinetics in Special Populations:

• Renal Impairment (RI): Janagliflozin demonstrates a highly favorable and stable PK profile in the setting of renal impairment. Studies have shown that its plasma exposure (AUC) is only slightly increased as renal function declines, with a reported 11% increase in AUC in patients with moderate RI compared to those with normal renal function. This contrasts with many other antidiabetic drugs that require significant dose adjustments or are contraindicated in renal impairment due to accumulation. This stability simplifies dosing and enhances the drug's potential safety profile in a complex patient population. Interestingly, exposure to the metabolite XZP-5185 was found to decrease in patients with mild to moderate RI.
• Hepatic Impairment: While clinical data are lacking, a physiologically based pharmacokinetic (PBPK) model was developed to predict Janagliflozin's behavior in patients with liver cirrhosis. The model predicted that Janagliflozin exposure would increase with the severity of cirrhosis (Child-Pugh classes A, B, and C), suggesting that a risk-benefit assessment is warranted when considering its use in patients with significant liver disease.

Parameter	Healthy Subjects	T2DM Patients	Notes / Source(s)
Tmax​ (median)	2.0–4.5 hours	2.0–6.0 hours	Rapid oral absorption
t1/2​ at steady state	~26–30 hours	~21–23 hours	Supports once-daily dosing
Dose Proportionality	Roughly dose-dependent increase in plasma exposure	Dose-proportional increase in plasma exposure	Consistent behavior across dose ranges
Accumulation Factor	Not specified	< 2	No significant accumulation with multiple doses
Effect of Renal Impairment on AUC	N/A	~11% increase in moderate RI vs. normal renal function	PK profile is stable in renal impairment
Effect of Liver Cirrhosis on AUC (predicted)	N/A	Predicted to increase with severity of cirrhosis	PBPK modeling suggests caution in liver disease

Clinical Development and Efficacy in Type 2 Diabetes Mellitus

The clinical development of Janagliflozin was strategically designed to establish its efficacy and safety profile efficiently, primarily focusing on the Chinese population with T2DM. This program culminated in two pivotal Phase 3 trials that supported its regulatory approval in China.

Overview of Clinical Trial Program

The core of Janagliflozin's clinical evidence comes from two key Phase 3 studies: one evaluating its use as monotherapy in drug-naive patients (NCT03811548) and another assessing it as an add-on therapy to metformin (NCT03851432). Both trials were multicenter, randomized, double-blind, and placebo-controlled, with a 24-week primary efficacy period followed by a 28-week extension period, providing data over a total of 52 weeks.

A defining feature of Janagliflozin's development was the sophisticated application of a Model-Informed Drug Development (MIDD) strategy. This approach involved constructing mechanistic pharmacokinetic/pharmacodynamic (PK/PD) models using preclinical and Phase 1 data. These models were then integrated with data from a model-based meta-analysis (MBMA) of the broader SGLT2 inhibitor class to predict the drug's long-term efficacy on HbA1c​ in T2DM patients. The strength and reliability of these predictions were sufficient to convince regulators to grant a waiver for a traditional, large-scale Phase 2 dose-ranging study. This strategic use of computational modeling significantly accelerated the drug's development timeline, allowing it to proceed directly to Phase 3 trials after early-phase studies were completed. This represents a modern, efficient approach to drug development, reducing both time and cost to market.

Efficacy as Monotherapy (NCT03811548)

This Phase 3 trial enrolled 432 drug-naive Chinese patients with T2DM who had inadequate glycemic control with diet and exercise alone. Patients were randomized to receive once-daily Janagliflozin 25 mg, Janagliflozin 50 mg, or placebo.

Primary Endpoint (Change in HbA1c​ at 24 weeks): The trial met its primary endpoint with high statistical significance.

• The placebo-adjusted least squares mean change in HbA1c​ was -0.80% for the Janagliflozin 25 mg group (95% CI -0.98% to -0.62%; p < 0.001).
• For the Janagliflozin 50 mg group, the placebo-adjusted reduction was -0.88% (95% CI -1.06% to -0.70%; p < 0.001).

Secondary Endpoints: Janagliflozin also demonstrated significant improvements across multiple secondary endpoints at 24 weeks.

• Glycemic Target Achievement: A significantly higher proportion of patients achieved an HbA1c​ target of <7.0%: 47.2% in the 25 mg group and 49.3% in the 50 mg group, compared to only 23.5% in the placebo group.
• Other Glycemic and Metabolic Parameters: Both doses led to statistically significant reductions versus placebo in fasting plasma glucose (FPG), 2-hour postprandial glucose (PPG), body weight, and systolic blood pressure (SBP) (p < 0.05 for all). Furthermore, treatment resulted in significant increases in high-density lipoprotein (HDL) cholesterol and improvements in insulin sensitivity.
• Long-Term Efficacy: These beneficial effects on glycemic and metabolic parameters were sustained throughout the subsequent 28-week extension period, demonstrating the durability of the treatment effect over 52 weeks.

Efficacy as Add-On Therapy to Metformin (NCT03851432)

This trial evaluated Janagliflozin in 421 Chinese patients with T2DM who were inadequately controlled on a stable dose of metformin monotherapy. Patients were randomized to receive once-daily Janagliflozin 25 mg, Janagliflozin 50 mg, or placebo, in addition to their ongoing metformin therapy.

Primary Endpoint (Change in HbA1c​ at 24 weeks): The results were again highly statistically significant.

• The placebo-adjusted least squares mean change in HbA1c​ was -0.58% for the Janagliflozin 25 mg group (p < 0.0001).
• The placebo-adjusted reduction for the Janagliflozin 50 mg group was identical at -0.58% (p < 0.0001).

The identical efficacy of the 25 mg and 50 mg doses in this add-on setting is a critical clinical finding. It suggests that in patients already receiving metformin, the additional glycemic benefit from SGLT2 inhibition is maximized at the 25 mg dose. This observation is mechanistically supported by the pharmacodynamic data showing a plateau in urinary glucose excretion at doses above 25 mg. This implies that for glycemic control in this combination, the 25 mg dose is the most efficient, and routine use of the 50 mg dose may be clinically redundant.

Secondary Endpoints: Similar to the monotherapy trial, Janagliflozin provided broad metabolic benefits when added to metformin.

• Glycemic Target Achievement: The proportion of patients achieving an HbA1c​ <7.0% was significantly higher in the active treatment groups: 41.8% (25 mg) and 41.7% (50 mg), versus 28.0% for placebo.
• Other Metabolic Parameters: Both doses produced significant reductions versus placebo in FPG, 2-hour PPG, body weight, and SBP, along with improvements in HDL cholesterol and insulin sensitivity (p < 0.05 for all).
• Long-Term Efficacy: These trends of improvement were retained during the 28-week extension period, confirming the sustained efficacy of the combination therapy over one year.

Safety, Tolerability, and Risk Management

The safety and tolerability of a new therapeutic agent are paramount considerations. The clinical development program for Janagliflozin provides a solid foundation for its safety profile, which is further contextualized by the extensive data available for the SGLT2 inhibitor class.

Comprehensive Safety Profile from Clinical Trials

Across its pivotal Phase 3 trials, Janagliflozin was demonstrated to be generally well-tolerated.

Overall Adverse Event (AE) Incidence: In the 24-week monotherapy trial, the overall incidence of AEs was slightly higher in the active treatment groups compared to placebo but did not suggest a significant safety concern. The rates were 67.8% for the 25 mg group, 71.5% for the 50 mg group, and 60.7% for the placebo group.

Key Safety Endpoints:

• Serious Adverse Events (SAEs): No serious adverse events were reported in a study of Janagliflozin in patients with renal impairment. Data from the broader Phase 3 program indicate that Janagliflozin did not increase the risk of SAEs compared to placebo.
• Hypoglycemia: Consistent with its insulin-independent mechanism of action, Janagliflozin carries a low risk of hypoglycemia. Critically, no episodes of severe hypoglycemia occurred throughout the entire 52-week treatment periods in either the monotherapy or the add-on to metformin trials.
• Genital Mycotic Infections (GMIs) and Urinary Tract Infections (UTIs): These are the most common class-specific side effects of SGLT2 inhibitors, driven by increased glucose in the urinary tract which can promote microbial growth. For Janagliflozin, the incidence of both UTIs and GMIs was explicitly reported as "low" in the monotherapy trial. While specific percentages are not provided in the abstracts, this qualitative description is a positive safety signal. If this finding of a genuinely lower incidence compared to competitors is substantiated by post-marketing and real-world data, it could represent a meaningful clinical advantage, potentially improving patient adherence and tolerability.
• Diabetic Ketoacidosis (DKA): This is a rare but serious potential side effect of the SGLT2 inhibitor class. Reassuringly, no cases of DKA were reported in the Janagliflozin Phase 3 program.

Class-Specific Safety Considerations

While Janagliflozin's own trial data are favorable, prescribers must consider the established safety profile of the SGLT2 inhibitor class as a whole.

• Diabetic Ketoacidosis (DKA): A warning for DKA is present on the labels of all approved SGLT2 inhibitors. This serious condition can be life-threatening and may present with atypical, near-normal blood glucose levels ("euglycemic DKA"). Key risk factors include any state of insulin deficiency (e.g., dose reduction, pancreatic disease), acute illness, surgery, caloric restriction (including ketogenic diets), and excessive alcohol consumption. Patients should be educated on the symptoms (nausea, vomiting, abdominal pain, shortness of breath) and advised to seek immediate medical attention if they occur.
• Volume Depletion and Hypotension: The osmotic diuretic effect of SGLT2 inhibitors can lead to intravascular volume contraction, which may manifest as symptomatic hypotension, dizziness, or acute kidney injury. The risk is elevated in elderly patients, those with pre-existing renal impairment, and individuals taking loop diuretics or other antihypertensive medications. It is recommended to assess and correct a patient's volume status before initiating therapy.
• Serious Urinary Tract Infections: While common UTIs can occur, post-marketing reports for the class have included rare cases of serious infections, such as urosepsis and pyelonephritis, requiring hospitalization.
• Necrotizing Fasciitis of the Perineum (Fournier's Gangrene): A very rare but severe and life-threatening bacterial infection of the perineal tissue has been reported with SGLT2 inhibitors. This constitutes a medical emergency requiring immediate surgical and antibiotic intervention.
• Other Potential Risks: An increased risk of lower-limb amputation and bone fractures was observed in some trials with canagliflozin, but this has not been established as a definitive class-wide effect and is not currently associated with Janagliflozin.

Contraindications and Precautions (Inferred)

Based on the data for Janagliflozin and the established profile of the SGLT2 inhibitor class, the following contraindications and precautions can be inferred:

• Contraindications: A history of serious hypersensitivity reaction to Janagliflozin or its excipients. Use in patients on dialysis is also contraindicated. The drug is not indicated for the treatment of Type 1 Diabetes Mellitus due to the significantly increased risk of DKA.
• Precautions: Renal function should be assessed prior to initiation and monitored periodically. Caution is advised in patients with risk factors for DKA, volume depletion, or recurrent genital infections. Temporary interruption of therapy should be considered during periods of acute illness, prolonged fasting, or major surgery.

Adverse Event	Monotherapy Trial (24 Weeks)	Notes
Any Adverse Event (%)	Placebo: 60.7% Jana 25 mg: 67.8% Jana 50 mg: 71.5%	Overall incidence was comparable between active and placebo groups
Severe Hypoglycemia (n)	0 in all groups	Consistent with insulin-independent mechanism
Diabetic Ketoacidosis (n)	0 in all groups	No cases observed in the pivotal trial program
Urinary Tract Infections	Incidence reported as "low"	A positive safety signal, but requires quantification from full study reports
Genital Mycotic Infections	Incidence reported as "low"	A potential point of differentiation if confirmed in real-world use

Dosage, Administration, and Special Populations

The appropriate use of Janagliflozin requires an understanding of its recommended dosing, administration, and application in specific patient populations, particularly those with common comorbidities like renal or hepatic disease.

Recommended Dosing Regimen

Based on the successful outcomes of its Phase 3 clinical trials, Janagliflozin is administered orally as a once-daily tablet. The doses approved for use in China are 25 mg and 50 mg.

The clinical evidence provides clear guidance for dose selection. In the add-on to metformin trial, the 25 mg and 50 mg doses demonstrated identical efficacy in reducing HbA1c​. This, combined with the pharmacodynamic data showing a plateau in urinary glucose excretion above the 25 mg dose, strongly suggests that

25 mg once daily is the optimal and most efficient therapeutic dose for the majority of patients requiring glycemic control. The 50 mg dose did show a slight numerical advantage in the monotherapy trial, but its lack of additional benefit in the more common combination-therapy setting makes the 25 mg dose the logical starting and standard maintenance dose.

Use in Specific Patient Populations

The use of any antidiabetic medication must be carefully considered in populations with altered physiology or limited clinical data.

Renal Impairment: Janagliflozin exhibits a particularly favorable profile for use in patients with chronic kidney disease (CKD), a common comorbidity in T2DM.

• The drug's pharmacokinetic profile is remarkably stable, with only a minor (~11%) increase in drug exposure observed in patients with moderate renal impairment. This stability reduces the risk of drug accumulation and simplifies dosing.
• Crucially, Janagliflozin maintains its pharmacodynamic effect of promoting urinary glucose excretion even in patients with moderate renal impairment (eGFR 30-59 mL/min/1.73 m²). While the absolute glucose-lowering efficacy of all SGLT2 inhibitors diminishes as GFR declines (because less glucose is filtered), the sustained pharmacologic activity may still contribute to the natriuretic, diuretic, and other hemodynamic effects thought to drive the cardiorenal protective benefits of the class. This makes Janagliflozin a promising option for this large and complex patient population, pending dedicated outcome trials.

Hepatic Impairment: There are no direct clinical trial data for Janagliflozin in patients with hepatic impairment. However, physiologically based pharmacokinetic (PBPK) modeling predicts that drug exposure increases with the severity of liver cirrhosis. This suggests that a careful risk-benefit assessment is necessary for patients with liver disease. For comparator SGLT2 inhibitors, prescribing information generally indicates no dose adjustment is needed for mild-to-moderate hepatic impairment, but use is not recommended in patients with severe impairment. A similar approach would be prudent for Janagliflozin.

Geriatric Population: Specific studies of Janagliflozin in the elderly have not been published. However, extensive data for the SGLT2 inhibitor class show that these drugs are effective and generally safe in older adults. The primary concern in this population is an increased risk of volume depletion-related adverse events, such as dehydration, postural dizziness, and hypotension, due to age-related declines in renal function and fluid homeostasis. Therefore, while Janagliflozin can likely be used effectively in the elderly, careful monitoring of volume status and renal function is warranted.

Pediatric Population: There are no data on the use of Janagliflozin in pediatric patients. Recently, other SGLT2 inhibitors like empagliflozin and dapagliflozin have received regulatory approval from the FDA for use in children aged 10 years and older with T2DM. These approvals were based on dedicated pediatric trials. However, these studies also noted a higher risk of hypoglycemia in the pediatric population compared to adults. The use of Janagliflozin in children is not established and would require dedicated clinical trials.

Pregnancy and Lactation: No clinical data are available for Janagliflozin in pregnant or lactating women. The SGLT2 inhibitor class is not recommended for use during pregnancy, particularly during the second and third trimesters. Animal studies have shown adverse effects on renal development during periods corresponding to these trimesters in humans. Similarly, because the drugs are excreted into animal milk and human kidney maturation continues for the first two years of life, there is a potential risk to the developing infant kidney. Therefore, breastfeeding is not recommended while taking SGLT2 inhibitors.

Comparative Landscape and Strategic Positioning

To fully appreciate Janagliflozin's clinical value and market potential, it must be evaluated within the context of the highly competitive SGLT2 inhibitor landscape, which is dominated by globally established agents such as dapagliflozin, empagliflozin, and canagliflozin.

Direct Comparison with Dapagliflozin

A key study in Janagliflozin's development program was a head-to-head trial in Chinese patients with T2DM that directly compared Janagliflozin (25 mg and 50 mg) with dapagliflozin 10 mg. The results of this study are central to its initial positioning. The trial concluded that Janagliflozin exhibited favorable pharmacokinetic, pharmacodynamic, and tolerability profiles that were

comparable to those of dapagliflozin 10 mg. In terms of the primary pharmacodynamic endpoint, both the 25 mg and 50 mg doses of Janagliflozin produced a slightly higher mean 24-hour urinary glucose excretion (UGE) compared to dapagliflozin 10 mg (approximately 92-94 g vs. 88 g, respectively). This direct comparison establishes Janagliflozin as a non-inferior, and potentially slightly more potent in terms of glucosuria, alternative to a leading SGLT2 inhibitor, at least within the studied population.

Indirect Comparison with Other SGLT2 Inhibitors

While direct comparative data with empagliflozin and canagliflozin are not available, an indirect comparison can be made based on their respective clinical trial data.

• Glycemic Efficacy: The placebo-adjusted HbA1c​ reductions observed with Janagliflozin monotherapy (-0.80% to -0.88%) are robust and fall squarely within the range reported for other SGLT2 inhibitors in similar monotherapy trials. This suggests that, purely as a glucose-lowering agent, Janagliflozin is a peer to the other members of its class.
• Pharmacokinetics: Janagliflozin possesses a notably longer terminal half-life (approximately 21-30 hours) compared to canagliflozin (~11-13 hours), dapagliflozin (~13 hours), and empagliflozin (~12 hours). While the clinical significance of this difference may be minor since all four drugs support convenient once-daily dosing, the longer half-life could theoretically provide more consistent SGLT2 inhibition over the 24-hour dosing interval.
• Safety Profile: The most significant potential differentiator lies in the safety profile. While the "low" reported incidence of UTIs and GMIs for Janagliflozin is promising, these remain the most common adverse events for the class as a whole. Canagliflozin carries specific warnings from the FDA regarding an increased risk of lower-limb amputation and bone fractures based on its cardiovascular outcomes trial (CVOT) data; these specific risks have not been associated with Janagliflozin or other SGLT2 inhibitors to the same degree.
• Cardiorenal Outcomes: This is the most critical point of differentiation in the current therapeutic environment. Canagliflozin (CANVAS program), dapagliflozin (DECLARE-TIMI 58, DAPA-HF, DAPA-CKD), and empagliflozin (EMPA-REG OUTCOME, EMPEROR program, EMPA-KIDNEY) have all successfully completed large-scale, multi-year CVOTs. These trials have unequivocally demonstrated that these drugs provide significant benefits in reducing major adverse cardiovascular events, hospitalizations for heart failure, and the progression of chronic kidney disease. These proven benefits have led to expanded indications beyond T2DM glycemic control and have redefined the standard of care. Janagliflozin currently lacks this high level of evidence.

Strategic Positioning and Market Outlook

Janagliflozin's current market strategy appears to be a "fast-follower" approach, focused on establishing a strong presence within the domestic Chinese market. This strategy leverages several key advantages: its status as a domestically developed innovative drug, a clinical profile that is comparable to established multinational brands, and a development pathway that was significantly accelerated by the use of MIDD. This allows it to compete effectively against existing, and likely more expensive, foreign-developed drugs for the primary indication of glycemic control in T2DM.

The company's ownership of international patents in the United States, Europe, Japan, and other regions indicates a long-term ambition for global expansion. However, its future outside of China is entirely contingent on its ability to generate the type of evidence that now defines the SGLT2 inhibitor class. To be competitive on a global scale, Janagliflozin will need to undergo its own large-scale CVOT. Without data demonstrating, at a minimum, cardiovascular non-inferiority, and ideally, superiority on hard cardiorenal endpoints, it will be unable to compete for the lucrative and clinically vital indications in heart failure and chronic kidney disease, which are now the primary drivers of SGLT2 inhibitor prescribing in many parts of the world.

Conclusion and Expert Recommendations

Synthesis of Findings

Janagliflozin is a potent, selective, and orally active SGLT2 inhibitor that has demonstrated robust glycemic and metabolic efficacy in patients with Type 2 Diabetes Mellitus. Clinical data from its Phase 3 program, conducted within the Chinese population, establish its non-inferiority to established agents in its class, such as dapagliflozin, for the primary endpoint of glucose lowering. Its favorable pharmacokinetic profile, characterized by a long half-life suitable for once-daily dosing and notable stability in patients with moderate renal impairment, is a significant clinical advantage. Furthermore, its development was distinguished by the innovative and successful application of a Model-Informed Drug Development strategy, which accelerated its path to market. The safety profile observed in clinical trials appears favorable, with no reports of severe hypoglycemia or diabetic ketoacidosis and a reportedly low incidence of common class-related adverse events.

Strategic Analysis

The approval of Janagliflozin in China represents a major achievement for Sihuan Pharmaceutical and its subsidiary Huisheng Biopharmaceutical. It validates their capacity for innovative drug development and positions them to compete effectively in the large and growing domestic diabetes market. The current strategy appears focused on leveraging its status as a domestically developed alternative to established multinational products for T2DM management.

Future Directions and Recommendations

While Janagliflozin is a clinically effective and safe treatment for T2DM, its long-term success and global potential are contingent on further strategic development. The following recommendations are proposed:

1. Initiate a Cardiovascular Outcome Trial (CVOT): To achieve global competitiveness and expand its indications beyond simple glycemic control, investment in a large-scale, multicenter CVOT is imperative. The standard for the SGLT2 inhibitor class is no longer just glucose control but proven cardiorenal protection. Such a trial should be designed to assess, at a minimum, cardiovascular non-inferiority, with a design powered to detect potential superiority on key composite endpoints, including MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke), hospitalization for heart failure, and progression of renal disease.
2. Pursue Indication Expansion in Heart Failure and CKD: Based on the robust class-wide evidence demonstrating profound benefits in these conditions, dedicated clinical development programs should be initiated to explore the efficacy of Janagliflozin in patients with heart failure (with both reduced and preserved ejection fraction) and chronic kidney disease, irrespective of their diabetic status. Success in these areas would unlock significant market potential and align Janagliflozin with the current standard of care.
3. Conduct Post-Marketing Surveillance and Real-World Evidence Studies: Rigorous post-marketing surveillance and the generation of real-world evidence in China are critical. These studies should aim to confirm the favorable safety profile observed in the controlled trial setting, with a particular focus on quantifying the incidence of UTIs and GMIs to validate the "low" incidence reported in Phase 3 trials.

In its current state, Janagliflozin is a valuable addition to the therapeutic armamentarium for T2DM in China. It possesses the fundamental pharmacological characteristics of a drug with significant global potential. However, realizing this potential will require a substantial commitment to generating the high-level, long-term outcomes data that have become the hallmark of the SGLT2 inhibitor class.

Works cited

1. Sihuan Pharmaceutical Holdings Group Ltd. - HKEXnews, accessed September 6, 2025, https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0123/2024012300005.pdf
2. Janagliflozin - Wikipedia, accessed September 6, 2025, https://en.wikipedia.org/wiki/Janagliflozin
3. Janagliflozin | New Drug Approvals, accessed September 6, 2025, https://newdrugapprovals.org/2025/08/25/janagliflozin/
4. Janagliflozin - Sihuan Pharmaceutical Holdings Group - AdisInsight - Springer, accessed September 6, 2025, https://adisinsight.springer.com/drugs/800041500
5. What is the therapeutic class of Janagliflozin? - Patsnap Synapse, accessed September 6, 2025, https://synapse.patsnap.com/article/what-is-the-therapeutic-class-of-janagliflozin
6. What is the mechanism of Janagliflozin? - Patsnap Synapse, accessed September 6, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-janagliflozin
7. Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/36594724/
8. Efficacy and safety of janagliflozin as add-on therapy to metformin in ..., accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/36433709/
9. Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/365769165_Efficacy_and_safety_of_janagliflozin_as_add-on_therapy_to_metformin_in_Chinese_patients_with_type_2_diabetes_inadequately_controlled_with_metformin_alone_A_multicentre_randomized_double-blind_placebo-
10. Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/371376631_Pharmacokinetics_Pharmacodynamics_and_Safety_of_Janagliflozin_in_Chinese_Type_2_Diabetes_Mellitus_Patients_with_Renal_Impairment
11. 153-LB: Pharmacokinetics, Pharmacodynamics, and Tolerability of ..., accessed September 6, 2025, https://diabetesjournals.org/diabetes/article/68/Supplement_1/153-LB/59513/153-LB-Pharmacokinetics-Pharmacodynamics-and
12. Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitus - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/32744380/
13. Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/37284974/
14. janagliflozin / Sihuan Pharmaceutical - LARVOL DELTA, accessed September 6, 2025, https://delta.larvol.com/Products/?ProductId=febec846-844b-42e4-b548-4ad9f9e555ff
15. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/36802026/
16. Sihuan's Abstracts regarding Clinical Trial Progress of SGLT-2, accessed September 6, 2025, https://www.biospace.com/sihuan-s-abstracts-regarding-clinical-trial-progress-of-sglt-2-inhibitor-selected-for-poster-presentation-at-the-american-diabetes-association-s-scientific-sessions
17. An Overview of New Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetes Mellitus | Nieczyporuk | Journal of Endocrinology and Metabolism, accessed September 6, 2025, https://jofem.org/index.php/jofem/article/view/942/284284710
18. Sodium-Glucose Transporter 2 Inhibitors | DrugBank Online, accessed September 6, 2025, https://go.drugbank.com/categories/DBCAT004076
19. Canagliflozin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 6, 2025, https://go.drugbank.com/drugs/DB08907
20. (PDF) Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: A case report - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/338499571_Severe_intoxication_caused_by_sodium-glucose_cotransporter_2_inhibitor_overdose_A_case_report
21. Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6953132/
22. An Update on SGLT2 Inhibitors for the Treatment of Diabetes Mellitus - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6028052/
23. Managing the side effects of sodium-glucose cotransporter-2 inhibitors, accessed September 6, 2025, https://www.ccjm.org/content/92/8/503
24. Year in Review 2024-2025: Cutting-Edge Research on SGLT2 Inhibitors, accessed September 6, 2025, https://wirelesslifesciences.org/2025/07/year-in-review-2024-2025-cutting-edge-research-on-sglt2-inhibitors/
25. Janagliflozin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 6, 2025, https://go.drugbank.com/drugs/DB16209
26. Janagliflozin | CAS#1800115-22-3 | biomolecule - MedKoo Biosciences, accessed September 6, 2025, https://www.medkoo.com/products/38505
27. janagliflozin | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 6, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=13950
28. Janagliflozin - PubChem, accessed September 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Janagliflozin
29. 162-LB: Pharmacokinetics, Pharmacodynamics, and Tolerability of Single- and Multiple-Dose of Janagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus, accessed September 6, 2025, https://diabetesjournals.org/diabetes/article/68/Supplement_1/162-LB/59537/162-LB-Pharmacokinetics-Pharmacodynamics-and
30. Pharmacokinetics, Pharmacodynamics, and Tolerability of Single- and Multiple-Doses of Janagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Chinese Subjects with Type 2 Diabetes Mellitus - FirstWord Pharma, accessed September 6, 2025, https://firstwordpharma.com/story/5081925
31. Janagliflozin - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 6, 2025, https://synapse.patsnap.com/drug/73336b28c2ba4443a6aff49791c321d0
32. Comparison of INVOKANA to Other SGLT2 Inhibitors - J&J Medical Connect, accessed September 6, 2025, https://www.jnjmedicalconnect.com/products/invokana/medical-content/comparison-of-invokana-to-other-sglt2-inhibitors
33. Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/36162752/
34. Prediction of Janagliflozin Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Liver Cirrhosis or Renal Impairment Using a Physiologically Based Pharmacokinetic Model | Request PDF - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/363796956_Prediction_of_Janagliflozin_Pharmacokinetics_in_Type_2_Diabetes_Mellitus_Patients_with_Liver_Cirrhosis_or_Renal_Impairment_Using_a_Physiologically_Based_Pharmacokinetic_Model
35. Janagliflozin Unknown Status Phase 3 Trials for Type 2 Diabetes Mellitus Treatment, accessed September 6, 2025, https://go.drugbank.com/drugs/DB16209/clinical_trials?conditions=DBCOND0029752&phase=3&purpose=treatment&status=unknown_status
36. 154-LB: Accelerating Clinical Development of Janagliflozin, a Novel Antidiabetic Drug, Using Model-Informed Drug Development Strategy | Diabetes, accessed September 6, 2025, https://diabetesjournals.org/diabetes/article/68/Supplement_1/154-LB/59562/154-LB-Accelerating-Clinical-Development-of
37. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor | Request PDF - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/368656235_A_Model-Informed_Approach_to_Accelerate_the_Clinical_Development_of_Janagliflozin_an_Innovative_SGLT2_Inhibitor
38. Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/366841164_Efficacy_and_safety_of_janagliflozin_monotherapy_in_Chinese_patients_with_type_2_diabetes_mellitus_inadequately_controlled_on_diet_and_exercise_A_multicentre_randomized_double-blind_placebo-controlled
39. Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis | BMJ Open, accessed September 6, 2025, https://bmjopen.bmj.com/content/15/2/e088687
40. Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/40010842/
41. Canagliflozin - StatPearls - NCBI Bookshelf, accessed September 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK603733/
42. Jardiance: Package Insert / Prescribing Information - Drugs.com, accessed September 6, 2025, https://www.drugs.com/pro/jardiance.html
43. Invokana (canagliflozin) dosing, indications, interactions, adverse effects, and more, accessed September 6, 2025, https://reference.medscape.com/drug/invokana-canagliflozin-999811
44. Canagliflozin Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 6, 2025, https://www.drugs.com/dosage/canagliflozin.html
45. 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVOKANA safely and e - Janssen, accessed September 6, 2025, https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf
46. Dosing | INVOKANA® (canagliflozin) HCP, accessed September 6, 2025, https://www.invokanahcp.com/dosing/
47. SGLT2 Inhibitors for Type 1 Diabetes: Pros, Cons, and Off-Label Use Explained, accessed September 6, 2025, https://abovediabetes.com/sglt2-inhibitors-for-type-1-diabetes-pros-cons-and-off-label-use-explained/
48. New Real-World Analysis Shows INVOKANA® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines, accessed September 6, 2025, https://www.jnj.com/media-center/press-releases/new-real-world-analysis-shows-invokana-canagliflozin-and-other-sglt2-inhibitors-reduced-the-risk-of-death-and-cardiovascular-events-compared-to-other-diabetes-medicines
49. What are the contraindications for Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitors? - Dr.Oracle AI, accessed September 6, 2025, https://droracle.ai/articles/83822/what-are-the-contraindications-for-sodium-glucose-linked-transporter-2-sglt2-inhibitors
50. SGLT2 inhibitors approved for T2DM only | Therapeutic Goods Administration (TGA), accessed September 6, 2025, https://www.tga.gov.au/resources/publication/publications/sglt2-inhibitors-approved-t2dm-only
51. Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients in real life, accessed September 6, 2025, https://scielo.isciii.es/pdf/ijm/v5n3/2695-5075-ijm-5-3-118.pdf
52. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/35970329/
53. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9536439/
54. FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes, accessed September 6, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-new-class-medicines-treat-pediatric-type-2-diabetes
55. US FDA approves Jardiance ® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older - Boehringer Ingelheim, accessed September 6, 2025, https://www.boehringer-ingelheim.com/us/media/press-releases/fda-approves-treatment-option-t2d-children-10-and-older
56. FDA Approves First SGLT2 Inhibitor for Use in Children With Type 2 Diabetes, accessed September 6, 2025, https://www.pharmacytimes.com/view/fda-approves-first-sglt2-inhibitor-for-use-in-children-with-type-2-diabetes
57. Canagliflozin (Invokana) Use During Pregnancy - Drugs.com, accessed September 6, 2025, https://www.drugs.com/pregnancy/canagliflozin.html
58. Canagliflozin - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed September 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK500623/
59. Pregnancy, breastfeeding and fertility while taking empagliflozin - NHS, accessed September 6, 2025, https://www.nhs.uk/medicines/empagliflozin/pregnancy-breastfeeding-and-fertility-while-taking-empagliflozin/
60. SGLT2 Inhibitors: A Review of Canagliflozin - U.S. Pharmacist, accessed September 6, 2025, https://www.uspharmacist.com/article/sglt2-inhibitors-a-review-of-canagliflozin
61. AusPAR Attachment 1: Product Information for Empagliflozin [Jardiance] - Therapeutic Goods Administration (TGA), accessed September 6, 2025, https://www.tga.gov.au/sites/default/files/auspar-empagliflozin-171026-pi.pdf
62. Canagliflozin vs Empagliflozin Comparison - Drugs.com, accessed September 6, 2025, https://www.drugs.com/compare/canagliflozin-vs-empagliflozin
63. Empagliflozin vs Jardiance Comparison - Drugs.com, accessed September 6, 2025, https://www.drugs.com/compare/empagliflozin-vs-jardiance
64. Invokana (canagliflozin) FDA Approval History - Drugs.com, accessed September 6, 2025, https://www.drugs.com/history/invokana.html
65. Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7897568/